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data on patient demographics, functional status, and mobility, for consenting patients, 
and then the patients entered information regarding functional abilities, satisfaction, 
pain, quality of life and cost of care. RESULTS: A total of 43 patients participated in 
the pilot survey. Respondents were predominantly insured through Medicare (43%) 
and 68% were men. With regard to functional abilities, 19% of the consumers 
required help with at least one activity of daily living. The percent of consumers 
experiencing an improvement in their ability to perform activities such as exercise, 
walking, bathing and dressing independently, all after receiving their device ranged 
from 18% to 51 %. Consumers also reported improved mood (64.9%), high satisfac-
tion with their device (81.1%) and their provider (100%), and improved conﬁdence 
(73%) after using their device. Several patients reported problems with ability to pay 
the out-of-pocket costs for their device (12.5%) or to afford device repair costs (9%). 
CONCLUSIONS: Preliminary results suggest that collecting outcomes data on this 
population is feasible, and that patients are beneﬁting from their O&P devices, 
through improved functional ability and emotional status. The systematic collection 
of patient reported outcomes may help to demonstrate the comparative effectiveness 
and value of O&P devices, and ultimately inform health insurance coverage 
decisions.
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OBJECTIVES: Diagnostic laboratory tests may add critical information to guide 
treatment and improve patient outcomes, but payers have often questioned its value. 
We reviewed the methodology and results of published cost-utility analyses (CUAs) 
of laboratory tests through 2008. METHODS: We screened all papers related to labo-
ratory diagnostic tests in the Tufts Medical Center Cost-effectiveness Analysis Registry 
(www.cearegistry.org) which contains detailed information on over 2,000 published 
CUAs from 1976 to 2008. In addition to the standard auditing process, we recorded 
information on the reported test accuracy and IVD cost. We also captured whether 
any account was taken for potential value (or harm) unrelated to treatment conse-
quences such as the “reassurance value of testing” or additional anxiety produced by 
test information. RESULTS: We identiﬁed 141 published CUAs pertaining to diag-
nostic laboratory tests, which contained 433 separate incremental cost-effectiveness 
ratios (ICER). The number of publications has increased rapidly in recent years. The 
most common areas of clinical application were hematology/oncology (n = 42, 
29.8%), and OB/GYN (n = 36, 25.5%). Approximately 63% (89/141) of studies 
addressed the accuracy of the test. Only 10% (14/141) mentioned test safety or associ-
ated risks. A small number (n = 13, 9.2%) of CUAs mentioned or considered the 
potential value or harm of testing unrelated to treatment consequences. Over 55% of 
the reported ICERs were either dominant (more QALYs for less cost), or below 
$50,000 per QALY gained (in $US 2008). CONCLUSIONS: The number of CUAs 
evaluating laboratory tests technologies has increased substantially with applications 
to diverse clinical areas. The vast majority of CUAs have not attempted to measure 
the potential value or harms of diagnostic testing unrelated to treatment.
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OBJECTIVES: To assess the budget impact of introducing oral nutritional supple-
ments (ONS), being a medical nutrition product, in elderly patients from the perspec-
tive of the society in The Netherlands in 2009. METHODS: A model was developed 
to calculate the budgetary impact of using ONS in patients who are eligible for ONS 
due to disease-related malnutrition (DRM). The analysis is based on the cohort of 
elderly patients (>65 years) in the community setting in The Netherlands in 2009. The 
budget impact of ONS was assessed using a linear decision analytic model reﬂecting 
cost functions related with DRM. The model allowed the assessment of the cost 
reductions resulting from improvement in DRM due to treatment with ONS. Clinical 
probabilities and resource utilization were based on clinical trials and published litera-
ture; cost data were from ofﬁcial price tariffs. RESULTS: The use of ONS leads to 
annual cost savings of 313.3 million (18.9%), when all eligible patients are treated. 
The additional costs of ONS (357.0 million) are more than balanced by a reduction 
on other health care costs (370.3 million). Sensitivity analyses were performed on all 
parameters, including duration of treatment with ONS and the proportion of DRM. 
These results showed that the use of ONS in all sensitivity analyses leads to cost 
savings. CONCLUSIONS: This budget impact analysis shows that the use of ONS in 
eligible elderly patients in the community setting leads to a positive impact on the 
national health care budget in The Netherlands.
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OBJECTIVES: Parenteral nutrition (PN) is used with patients when oral or enteral 
nutrition isn’t possible or adequate. Compared to other therapeutic interventions, 
relatively little is known about the real-world use of PN, the characteristics of 
patients who receive it, or the incidence of adverse events. Our objective was to 
explore PN as it is currently utilized in the United States, using a large, nationally 
representative inpatient database. METHODS: We examined the Premier Perspec-
tiveTM database for all inpatients who received any PN between 2005 and 2007. 
Inpatients admitted with any outcome of interest (i.e., bacterial infection, hepatic 
dysfunction, hypoglycemia, acute cholecystitis, and phlebitis) were excluded. Hospital 
(e.g., bed size, geographic location, urban/rural status), patient (e.g., age, sex, comor-
bidities, severity), and PN characteristics were analyzed. RESULTS: Of over 11 
million inpatients in the database, 68,984 adult, 3,083 pediatric and 34,307 neonates 
received PN. The average age of the adult patients was 66. Whites had a dispro-
portionally higher probability of receiving PN (73.1%) than any other ethnic group. 
46.2% of PN adult patients received PN in hospitals with bed size of 250–499, 
followed by hospitals with bed size of 500–749 (31.5%), and hospitals with bed 
size 50–249 (20.3%). Among adult PN patients, 38.9% were diagnosed with a 
malignancy, followed by undernutrition 33.2%, renal failure 31.3%, diabetes 24.4%. 
peritonitis 9.0%, acute pancreatitis 8.4%, and cirrhosis 7.6%. Compared to neonates, 
the infection rates and bloodstream infection rates (BSI) of the adult population 
were much higher (infection, 49.0% vs. 10.7%; BSI 26.9% vs. 1.7%). Most patients 
were primarily diagnosed with intestinal or peritoneal adhesion with obstruction 
(ICD-9 560.81). The majority of PN adult patients used procedure of venous cath-
eterization (ICD-9 38.93). CONCLUSIONS: Large retrospective databases provide 
us with extraordinary insights to understand the characteristics of this vulnerable 
population and the real-world use of PN.
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OBJECTIVES: To assess the health economic impact of oral nutritional supplements 
(ONS), being a medical nutrition product, in elderly patients from the perspective of 
the society in The Netherlands in 2009. METHODS: This health economic analysis 
is based on a comparison of the use of ONS versus “no ONS” in patients who are 
eligible for ONS due to disease-related malnutrition (DRM). The base case analysis 
is based on a comparison in elderly patients (>65 years) in the community setting. The 
costs of the two treatment strategies ONS versus “no ONS” were assessed using a 
linear decision analytic model reﬂecting costs related with DRM. The model structure 
allowed for differences in costs for ONS and other resource utilization. Clinical prob-
abilities and resource utilization were based on clinical trials and published literature; 
cost data were from ofﬁcial price tariffs. RESULTS: The use of ONS reduces the total 
costs from 31353 to 31180, which corresponds with a 3173 (12.8%) cost savings per 
patient. The additional costs of ONS are more than balanced by a reduction on 
hospitalization costs. Sensitivity analyses were performed on all parameters, including 
the risk of hospitalization and improvement of DRM. These results showed that the 
use of ONS in all sensitivity analyses leads to cost savings. CONCLUSIONS: This 
health economic analysis shows that the use of ONS in elderly patients in the com-
munity setting is a cost-effective treatment in The Netherlands and is dominant over 
standard care without ONS: it leads to cost savings and a higher effectiveness.
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OBJECTIVES: To assess the health economic impact of oral nutritional supplements 
(ONS), being a medical nutrition product, in hospitalized patients from the society 
perspective in Germany in 2009. METHODS: This health economic analysis is based 
on a comparison of the use of ONS versus “no ONS” in hospitalized patients who 
are eligible for ONS due to disease-related malnutrition (DRM). The costs of the two 
treatment strategies ONS versus “no ONS” were assessed using a linear decision 
analytic model reﬂecting costs related with DRM. The model structure allowed for 
differences in costs for ONS and length of stay. Clinical probabilities and resource 
utilization were based on clinical trials and published literature; cost data were from 
ofﬁcial price tariffs. RESULTS: The use of ONS reduces the total costs from 34105 
to 33967, which corresponds with a 3138 cost savings per patient. The additional 
costs of ONS are more than balanced by a reduction on hospitalization costs. Sensitiv-
ity analyses were performed on all parameters, including length of stay and improve-
ment of DRM. These results showed that the use of ONS in all sensitivity analyses 
leads to cost savings. CONCLUSIONS: This health economic analysis shows that the 
use of ONS in patients in the hospital setting is a cost-effective treatment in Germany 
